Addex Historical Financial Ratios
| ADXN Stock | USD 10.60 0.76 7.72% |
Addex Therapeutics is presently reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 346 or Days Sales Outstanding of 32.52 will help investors to properly organize and evaluate Addex Therapeutics financial condition quickly.
Addex |
About Addex Financial Ratios Analysis
Addex TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Addex Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Addex financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Addex Therapeutics history.
Addex Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Addex Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Addex Therapeutics sales, a figure that is much harder to manipulate than other Addex Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Net Profit Margin
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.Most ratios from Addex Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.At this time, Addex Therapeutics' PTB Ratio is very stable compared to the past year. As of the 23rd of September 2024, Average Payables is likely to grow to about 1.4 M, while Price To Sales Ratio is likely to drop 222.62.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 40.6 | 153.53 | 34.23 | 32.52 | PTB Ratio | 231.12 | 107.09 | 329.97 | 346.47 |
Addex Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Addex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Addex Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 134.14 | 1.8K | 1.3K | 369.89 | 234.34 | 222.62 | |
| Ptb Ratio | 14.52 | 433.44 | 231.12 | 107.09 | 329.97 | 346.47 | |
| Days Sales Outstanding | 15.59 | 6.91 | 40.6 | 153.53 | 34.23 | 32.52 | |
| Book Value Per Share | 0.97 | 0.55 | 0.5 | 0.11 | 0.0154 | 0.0146 | |
| Free Cash Flow Yield | (0.0257) | (0.001933) | (0.003766) | (0.0312) | (0.0212) | (0.0222) | |
| Operating Cash Flow Per Share | (0.16) | 0.0752 | (0.36) | (0.46) | (0.43) | (0.11) | |
| Stock Based Compensation To Revenue | 0.61 | 0.33 | 0.4 | 2.59 | 1.11 | 1.06 | |
| Pb Ratio | 14.52 | 433.44 | 231.12 | 107.09 | 329.97 | 346.47 | |
| Ev To Sales | 122.93 | 1.7K | 1.3K | 365.26 | 232.15 | 220.55 | |
| Free Cash Flow Per Share | (0.17) | 0.0748 | (0.36) | (0.46) | (0.43) | (0.11) | |
| Roic | (0.59) | (0.82) | (0.9) | (3.91) | (6.92) | (6.57) | |
| Net Income Per Share | (0.56) | (0.48) | (0.45) | (0.46) | (0.14) | (0.15) | |
| Payables Turnover | 0.1 | 10.55 | 7.17 | 11.46 | 7.05 | 7.4 | |
| Sales General And Administrative To Revenue | 1.54 | 1.42 | 1.76 | 5.13 | 4.47 | 4.24 | |
| Research And Ddevelopement To Revenue | 4.51 | 2.87 | 4.4 | 10.31 | 1.7 | 1.62 | |
| Capex To Revenue | 0.0103 | 0.0164 | 0.0108 | 4.08E-4 | 0.004242 | 0.00403 | |
| Cash Per Share | 1.19 | 0.7 | 0.6 | 0.15 | 0.052 | 0.0494 | |
| Pocfratio | (39.09) | (519.91) | (266.1) | (32.01) | (47.29) | (49.66) | |
| Interest Coverage | (115.43) | (176.16) | (246.08) | (419.66) | (475.83) | (499.62) | |
| Capex To Operating Cash Flow | (0.003001) | (0.004878) | (0.002145) | (3.5E-5) | (8.56E-4) | (8.99E-4) | |
| Pfcf Ratio | (38.97) | (517.39) | (265.54) | (32.01) | (47.25) | (49.61) | |
| Days Payables Outstanding | 3.5K | 34.61 | 50.89 | 31.86 | 51.81 | 49.22 | |
| Roe | (0.58) | (0.88) | (0.91) | (4.23) | (9.22) | (8.75) | |
| Ev To Operating Cash Flow | (35.82) | (518.42) | (264.74) | (31.61) | (46.85) | (49.19) | |
| Pe Ratio | (25.07) | (492.47) | (254.89) | (25.29) | (35.81) | (37.6) | |
| Ev To Free Cash Flow | (35.71) | (515.9) | (264.18) | (31.61) | (46.81) | (49.15) | |
| Earnings Yield | (0.0399) | (0.002031) | (0.003923) | (0.0395) | (0.0279) | (0.0293) | |
| Net Debt To E B I T D A | 2.18 | 1.53 | 1.32 | 0.33 | 0.36 | 0.34 | |
| Current Ratio | 5.7 | 5.38 | 5.31 | 2.39 | 1.46 | 1.39 | |
| Tangible Book Value Per Share | 0.97 | 0.55 | 0.5 | 0.11 | 0.0154 | 0.0146 | |
| Receivables Turnover | 23.41 | 52.84 | 8.99 | 2.38 | 10.66 | 8.24 | |
| Graham Number | 3.49 | 2.44 | 2.24 | 1.06 | 0.22 | 0.21 |
Pair Trading with Addex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Addex Stock
| 0.75 | BNR | Burning Rock Biotech Upward Rally | PairCorr |
| 0.69 | DNA | Ginkgo Bioworks Holdings Trending | PairCorr |
| 0.56 | ONCT | Oncternal Therapeutics | PairCorr |
| 0.53 | MBIO | Mustang Bio | PairCorr |
| 0.53 | MNMD | Mind Medicine | PairCorr |
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Addex Stock
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.82) | Revenue Per Share 2.04 | Quarterly Revenue Growth (0.53) | Return On Assets (1.26) | Return On Equity (8.10) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.